COMPANY OVERVIEW

Anokion is focused on improving the treatment and outcomes of autoimmune disease. Our proprietary antigen-specific immune tolerance technology is designed to be both more effective and specific than the current standard of care.

---

LOCATION

Ecublens, , Switzerland

Cambridge, MA, USA

---

THERAPEUTIC AREAS

Autoimmune Disease

---

WEBSITE

https://anokion.com/

---

CAREER WEBSITE

https://anokion.com/careers/

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Sep 19, 2023

Anokion Announces Nature Biomedical Engineering Publication Further Validating its Immune Tolerance Approach to Treating Celiac Disease and Multiple Sclerosis

Sep 12, 2023

Anokion Announces Clinical Progress with KAN-101 and ANK-700

Sep 7, 2023

Anokion Strengthens its Senior Leadership with Promotions and New Appointment

Jun 15, 2023

Anokion Announces Publication in The Lancet Gastroenterology and Hepatology Highlighting Safety and Preliminary Effects of KAN-101 in Celiac Disease in its ACeD Phase 1 Clinical Trial

Jun 15, 2023

Anokion Announces Publication in The Lancet Gastroenterology and Hepatology Highlighting Safety and Preliminary Effects of KAN-101 in Celiac Disease in its ACeD Phase 1 Clinical Trial

For More Press Releases

---